Recombinant human TSH versus hypothyroidism. Cost-minimization-analysis in the follow-up care of differentiated thyroid carcinoma.

Dietlein, M; Busemeyer, S; Kobe, C; Schmidt, M; Theissen, P; Schicha, H

Dietlein, M; Busemeyer, S; Kobe, C; Schmidt, M; Theissen, P; Schicha, H.

Affiliation

Dietlein M; Klinik und Poliklinik für Nuklearmedizin des Universitätsklinikums Köln, Kerpener Str. 62, 50937 Köln, Germany. markus.dietlein@uni-koeln.de

Nuklearmedizin ; 49(6): 216-24, 2010.

Article in En | MEDLINE | ID: mdl-20877918

Subject(s)

Recombinant Proteins/therapeutic use; Thyroid Neoplasms/drug therapy; Thyrotropin/therapeutic use; Carcinoma; Carcinoma, Papillary; Fatigue/etiology; Female; Hospitalization; Humans; Hypothyroidism/chemically induced; Male; Recombinant Proteins/economics; Thyroglobulin/adverse effects; Thyroglobulin/blood; Thyroglobulin/drug effects; Thyroid Cancer, Papillary; Thyroid Neoplasms/blood; Thyrotropin/economics; Thyrotropin/genetics; Thyrotropin Alfa/therapeutic use

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Recombinant Proteins / Thyroid Neoplasms / Thyrotropin Type of study: Etiology_studies / Health_economic_evaluation Limits: Female / Humans / Male Language: En Journal: Nuklearmedizin Year: 2010 Type: Article Affiliation country: Germany

Fulltext

XML

PubMed Links

Search on Google